Key result
Novel cardioprotective therapies targeting mitochondria, inflammation, and ferroptosis show promise against ischemia-reperfusion injury.
Why the study?
Myocardial ischemia-reperfusion injury contributes substantially to infarct expansion and heart failure, yet translating experimental cardioprotective therapies into clinical practice has been challenging due to comorbidities, patient heterogeneity, and disease complexity.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiological mechanisms of myocardial ischemia-reperfusion injury, endogenous cardioprotective pathways, and emerging therapeutic targets such as mitochondrial-targeted antioxidants, ferroptosis inhibitors, and SGLT2 inhibitors.
Ischemic heart disease remains the leading cause of death worldwide and is frequently complicated by myocardial ischemia–reperfusion (I/R) injury, which contributes substantially to infarct expansion, adverse ventricular remodeling, and heart failure. The pathophysiology of myocardial ischemia involves a complex interplay among energy depletion, intracellular acidosis, calcium overload, oxidative stress, mitochondrial dysfunction, and the activation of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death pathways. Endogenous cardioprotective mechanisms, including ischemic preconditioning, postconditioning, remote ischemic conditioning, heat shock proteins, bilirubin signaling, and mitochondrial quality-control pathways, have demonstrated potent infarct-limiting effects in experimental models. These protective responses are mediated through interconnected signaling networks which converge to preserve mitochondrial integrity, maintain calcium homeostasis, reduce oxidative stress, and enhance cell survival. In addition, innate and adaptive immune responses play critical roles in post-infarction repair and remodeling, although excessive and/or prolonged inflammation can exacerbate injury. Despite strong mechanistic evidence, the translation of cardioprotective therapies into clinical practice has been challenging due to comorbidities, patient heterogeneity, and the complexity of human disease. Emerging approaches, including mitochondrial-targeted antioxidants, cell-based therapies, anti-inflammatory interventions, ferroptosis inhibitors, and SGLT2 inhibitors, offer promising opportunities for developing effective, multifaceted cardioprotective strategies.
No takes yet. Share an insight, caveat, or question.
Adenawoola et al. (2026) conducted a review in Myocardial ischemia and ischemia-reperfusion (I/R) injury. Cardioprotective therapies (e.g., ischemic conditioning, mitochondrial-targeted antioxidants, cell-based therapies, anti-inflammatory interventions, ferroptosis inhibitors, SGLT2 inhibitors) was evaluated. Emerging cardioprotective therapies targeting mitochondria, inflammation, ferroptosis, and SGLT2 offer promising multifaceted strategies against myocardial ischemia-reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: